Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy

Blog Article

tokidoki hello kitty blind box Antibody-based cancer immunotherapy has become a powerful asset in the arsenal against malignancies.In this regard, bispecific antibodies (BsAbs) are a ground-breaking novel approach in the therapy of cancers.Recently, BsAbs have represented a significant advancement in improving clinical outcomes.BsAbs are designed to target two different antigens specifically.Over a hundred various BsAb forms currently exist, and more are constantly being manufactured.

An antagonistic regulator of T cell activation is cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or CD152, a second counter-receptor for the B7 family of co-stimulatory molecules was introduced in 1996 by Professor James P.Allison and colleagues.Contrary to the explosive success of dual immune checkpoint blockade for treating cancers, a major hurdle still yet persist is that immune-related amina muaddi scarpe trasparenti adverse events (irAEs) observed by combining immune checkpoint inhibitors (ICIs) or monoclonal antibodies such as ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).A promising strategy to overcome this hurdle is using BsAbs.This article will summarize BsAbs targeting CTLA-4, their applications in cancer immunotherapy, and relevant clinical trial advances.

We will also discuss the pre-clinical rationale for using these BsAbs, and provide the current landscape of the field.